Home » Stocks » IMMP

Immutep Limited (IMMP)

Stock Price: $1.73 USD -0.06 (-3.35%)
Updated Oct 30, 2020 2:55 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 85.27M
Revenue (ttm) 11.38M
Net Income (ttm) -9.29M
Shares Out 49.29M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $1.73
Previous Close $1.79
Change ($) -0.06
Change (%) -3.35%
Day's Open 1.78
Day's Range 1.65 - 1.78
Day's Volume 90,635
52-Week Range 0.53 - 3.10

More Stats

Market Cap 85.27M
Enterprise Value 73.36M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 49.29M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.40
FCF / Share -0.22
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 399,294
Short Ratio 0.85
Short % of Float n/a
Beta 1.34
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.49
PB Ratio 3.67
Revenue 11.38M
Operating Income -8.49M
Net Income -9.29M
Free Cash Flow -7.49M
Net Cash 11.91M
Net Cash / Share 0.24
Gross Margin 100.00%
Operating Margin -74.61%
Profit Margin -81.60%
FCF Margin -65.81%
ROA -21.62%
ROE -46.69%
ROIC -133.70%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.58*
(164.74% upside)
Low
4.28
Current: $1.73
High
5.00
Target: 4.58
*Average 12-month USD price target from 3 stock analysts.

Financial Performance

Financial numbers in millions AUD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue16.507.497.354.222.032.093.144.014.201.07
Revenue Growth120.31%1.85%74.19%108.07%-3.06%-33.35%-21.6%-4.69%294.16%-
Gross Profit16.507.497.354.222.032.093.144.014.201.07
Operating Income-12.31-17.35-11.69-9.35-61.47-13.93-13.33-15.11-17.27-14.13
Net Income-13.47-18.34-12.75-9.37-62.02-32.15-13.34-15.23-19.94-21.08
Shares Outstanding33930320861.8552.5436.8631.9831.9831.9831.98
Earnings Per Share-0.34-0.55-0.46-0.40-2.78-2.34-3.10-4.73-6.40-12.47
Operating Cash Flow-10.84-15.29-7.78-8.51-11.31-7.79-14.23-16.04-19.12-12.82
Capital Expenditures-0.02-0.04-0.01-0.010.10-0.05-0.10-0.51-0.57-0.04
Free Cash Flow-10.86-15.33-7.79-8.51-11.21-7.84-14.33-16.55-19.69-12.87
Cash & Equivalents26.3216.5723.4812.2420.886.7623.2030.0238.0455.92
Total Debt9.057.646.655.785.031.51----
Net Cash / Debt17.278.9316.836.4615.855.2523.2030.0238.0455.92
Assets46.6040.5447.0034.9642.5530.9825.3832.8141.6157.64
Liabilities13.3016.1513.488.437.246.292.793.574.452.54
Book Value33.3024.3933.5226.5335.3224.6922.5929.2537.1655.10
Numbers in millions AUD, except per-share numbers.

Company Profile

Company Details

Full Name Immutep Limited
CEO Marc Voigt

Stock Information

Ticker Symbol IMMP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMMP

Description

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.